Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259280 | 0.89 | LRRK2 (0.47) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL4039259 | 0.87 | LRRK2 (0.47) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL4035683 | 0.83 | DYRK3 (0.48) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2203187 | 0.80 | NPC1 (0.46) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL4035827 | 0.80 | MEN1 (0.46) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2202126 | 0.77 | DYRK3 (0.48) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2229449 | 0.73 | TGFBR1 (0.56) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL2198086 | 0.70 | TGFBR1 (0.52) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL4035611 | 0.69 | LRRK2 (0.47) | PRKD1LRRK2RIPK2RIPK3TGFBR1 | |
| SCHEMBL21542003 | 0.67 | KDR (0.54) | IRAK4SMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | PRKD1 1569/4885LRRK2 3131/4885RIPK2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.